SCHEMBL5234499

SCHEMBL5234499

CCNc1ccc(-c2nc3c(C)nn(-c4ccccc4)c3c(=O)[nH]2)c(OC)c1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 3/20 0.48
PDE7A Q13946 2/20 0.47
PDE7B Q9NP56 1/20 0.47
PDE1A P54750 2/20 0.40
PDE1B Q01064 2/20 0.40
PDE1C Q14123 2/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
KMT2A Q03164 1/20 0.40
TP53 P04637 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CCNE1 P24864 2/20 0.39
CDK2 P24941 2/20 0.39
CDK1 P06493 1/20 0.39
CCNB1 P14635 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5232028 0.90 CFTR (0.46) PDE5APDE7APDE7BTP53POLB
SCHEMBL5231433 0.89 PDE7A (0.44) PDE5APDE7APDE7BALDH1A1HPGD
SCHEMBL5232040 0.86 PDE7A (0.47) PDE5APDE7APDE7BALDH1A1TP53
SCHEMBL5228844 0.85 PDE5A (0.54) PDE5APDE1APDE1BPDE1CMEN1
SCHEMBL5232006 0.84 PDE7A (0.65) PDE5APDE7APDE7B
SCHEMBL5233250 0.84 PDE7A (0.50) PDE5APDE7APDE7BMEN1ALDH1A1
SCHEMBL5229120 0.84 PDE7A (0.50) PDE5APDE7APDE7BMEN1KMT2A
SCHEMBL5234270 0.83 PDE5A (0.58) PDE5APDE7APDE7BPDE1APDE1B
SCHEMBL5234019 0.83 PDE7A (0.49) PDE5APDE7APDE7B
SCHEMBL5231578 0.82 PDE7A (0.49) PDE5APDE7APDE7B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1454897-B1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY ASUBIO PHARMA CO LTD (JP) 2007-10-10 EP disclosed
US-7268128-B2 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action AUSBIO PHARMA CO., LTD. (JP) 2007-09-11 US disclosed
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action OMEROS CORPORATION 2005-07-07 US disclosed
EP-1454897-A1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY Daiichi Suntory Pharma Co., Ltd. (JP) 2004-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action PDE7B, PDE3B, PDE3A PDE5A 8/4885PDE7A 4/4885PDE7B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.